Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | CCR1 | P32246 | 4/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP10 | P09238 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19430061 | 0.83 | PPID (0.38) | HRH3CCR1SMYD3MMP2MMP3 | |
| SCHEMBL19423717 | 0.83 | ALDH1A1 (0.38) | HRH3SMYD3TRPV1GAAALDH1A1 | |
| SCHEMBL19423585 | 0.82 | CYP4F2 (0.43) | TRPV1RIPK1 | |
| SCHEMBL19430058 | 0.78 | PPID (0.60) | HRH3CCR1SMYD3MMP2MMP3 | |
| SCHEMBL19421470 | 0.78 | PPID (0.60) | HRH3CCR1SMYD3MMP2MMP3 | |
| SCHEMBL19429687 | 0.78 | PPID (0.60) | HRH3CCR1SMYD3MMP2MMP3 | |
| SCHEMBL19410079 | 0.78 | PPID (0.60) | HRH3CCR1SMYD3MMP2MMP3 | |
| SCHEMBL19410081 | 0.78 | PPID (0.60) | HRH3CCR1SMYD3MMP2MMP3 | |
| SCHEMBL19421453 | 0.78 | PPID (0.60) | HRH3CCR1SMYD3MMP2MMP3 | |
| SCHEMBL19416126 | 0.75 | IAPP (0.45) | HRH3TRPV1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283425-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283425-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | PPIG, PPIH, FKBP2 | HRH3 3541/4885CCR1 2861/4885SMYD3 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.